Table 2.
Viremia Levels in Patients with Autoimmune Disease upon Planed Primary 17DD-YF Vaccination.
| Study groups | Viremia peak (day after vaccination) | Viremia level at peak (mean copies/mL)* | p Value |
|---|---|---|---|
| Health controls (HC) (n = 13) | Day 5–6 | 4.8 ± 3.8 × 103 | > 0.9999 |
| Autoimmune diseases (AID) (n = 86) | Day 5–6 | 5.5 ± 2.1 × 103 | > 0.9999 |
| AID/PRNT(−) (n = 15) | Day 5–6 | 0.8 ± 0.6 × 103 | > 0.9999 |
| AID/PRNT(+) (n = 71) | Day 5–6 | 6.6 ± 2.5 × 103 | > 0.9999 |
| Rheumatoid Arthritis (RA) (n = 24) | Day 5–6 | 1.6 ± 0.7 × 103 | > 0.9999 |
| Spondyloarthritis (SpA) (n = 29) | Day 5–6 | 6.1 ± 3.2 × 103 | > 0.9999 |
| Systemic Lupus Erythematosus (SLE) (n = 11) | Day 5–6 | 2.7 ± 2.6 × 103 | > 0.9999 |
| Sjögren’s Syndrome (SS) (n = 18) | Day 5–6 | 12.9 ± 8.4 × 103 | > 0.9999 |
* Data are reported as mean copies of 17DD-YF RNAnemia at peak ± standard error. No significant difference by no-parametric Kruskal–Wallis analysis (p = 0.5056) followed by Dunn’s post-test for sequential pairwise comparisons and a threshold p value of < 0.05 was considered for statistical significance.